Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
Vincerx Pharma, Inc. (VINC)
Company Research
Source: GlobeNewswire
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically In preclinical studies, Vincerx’s next-generation effector chemistry improves the efficacy of two approved antibody-drug conjugates (ADCs), highlighting VersAptx™ platform’s potential to advance cancer therapies Management to host a virtual investor event today at 2:00 PM PDT / 5:00 PM EDT PALO ALTO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Re
Show less
Read more
Impact Snapshot
Event Time:
VINC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VINC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VINC alerts
High impacting Vincerx Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
VINC
News
- Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsGlobeNewswire
- Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsGlobeNewswire
- Vincerx Pharma, Inc. (NASDAQ: VINC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Vincerx Pharma, Inc. (NASDAQ: VINC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
VINC
Sec Filings
- 4/29/24 - Form 424B5
- 4/26/24 - Form 8-K
- 4/25/24 - Form 8-K
- VINC's page on the SEC website